Cellectis S.A. logo

Cellectis S.A.

EPA:ALCLS.PA

Overview | Financials
Company Name Cellectis S.A.
Symbol ALCLS.PA
Currency EUR
Price 1.71
Market Cap 123,280,056
Dividend Yield 0%
52-week-range 1.634 - 3.44
Industry Biotechnology
Sector Healthcare
CEO Dr. Andre Choulika Ph.D.
Website https://www.cellectis.com

An error occurred while fetching data.

About Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies,

Related Stocks

DBV Technologies S.A. logo

DBV Technologies S.A.

DBV.PA

2.136 EUR

MedinCell S.A. logo

MedinCell S.A.

MEDCL.PA

17.94 EUR

UG Healthcare Corporation Limited logo

UG Healthcare Corporation Limited

8K7.SI

0.123 SGD

Genfit S.A. logo

Genfit S.A.

GNFT.PA

4.89 EUR

Nanobiotix S.A. logo

Nanobiotix S.A.

NANO.PA

3.954 EUR

Median Technologies SA logo

Median Technologies SA

ALMDT.PA

4.105 EUR

Amplitude Surgical SA logo

Amplitude Surgical SA

AMPLI.PA

3.16 EUR

Malin Corporation plc logo

Malin Corporation plc

MLC.IR

5.8 EUR

OSE Immunotherapeutics SA logo

OSE Immunotherapeutics SA

OSE.PA

9.9 EUR

Financials

Numbers are in millions USD

Numbers are in millions USD